TW200741003A - Modulation of peroxisome proliferator-activated receptors - Google Patents
Modulation of peroxisome proliferator-activated receptorsInfo
- Publication number
- TW200741003A TW200741003A TW095129257A TW95129257A TW200741003A TW 200741003 A TW200741003 A TW 200741003A TW 095129257 A TW095129257 A TW 095129257A TW 95129257 A TW95129257 A TW 95129257A TW 200741003 A TW200741003 A TW 200741003A
- Authority
- TW
- Taiwan
- Prior art keywords
- activated receptors
- modulation
- peroxisome proliferator
- reductase
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70789705P | 2005-08-12 | 2005-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200741003A true TW200741003A (en) | 2007-11-01 |
Family
ID=37737230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095129257A TW200741003A (en) | 2005-08-12 | 2006-08-09 | Modulation of peroxisome proliferator-activated receptors |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070037193A1 (zh) |
EP (1) | EP1803809A3 (zh) |
JP (1) | JP2007061093A (zh) |
KR (1) | KR20080014936A (zh) |
CN (1) | CN1916167A (zh) |
AR (1) | AR054909A1 (zh) |
AU (1) | AU2006203479A1 (zh) |
BR (1) | BRPI0603206A (zh) |
CA (1) | CA2553115A1 (zh) |
CO (1) | CO5780135A1 (zh) |
IL (1) | IL177407A0 (zh) |
MX (1) | MXPA06009161A (zh) |
NO (1) | NO20063652L (zh) |
SG (1) | SG130141A1 (zh) |
TW (1) | TW200741003A (zh) |
ZA (1) | ZA200606661B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1856085B1 (en) * | 2005-03-11 | 2015-07-08 | Howard Florey Institute Pty Ltd | Flavonoid compounds and uses thereof |
WO2009026657A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Flavonoid ppar agonists |
AU2009259543B2 (en) * | 2008-05-28 | 2015-09-03 | Basf Se | Means and methods for assessing increased peroxisomal proliferation |
JP2012513471A (ja) * | 2008-12-22 | 2012-06-14 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | アルツハイマー病および癌の治療のためのクマリン系化合物 |
EP2389459B1 (en) * | 2009-01-21 | 2014-03-26 | George Atanasoff | Methods and systems for control of a surface modification process |
EA015364B1 (ru) * | 2009-03-18 | 2011-06-30 | Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) | 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения |
US9752191B2 (en) * | 2009-07-09 | 2017-09-05 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
CN101948458B (zh) * | 2010-09-07 | 2012-11-07 | 中国药科大学 | 具有抗肿瘤活性的黄芩素衍生物及在医药上的应用 |
CN102964322A (zh) * | 2012-12-12 | 2013-03-13 | 中国药科大学 | 异黄酮或类黄酮脂肪醚类衍生物、其制备方法和医药用途 |
JP7029777B2 (ja) * | 2016-03-28 | 2022-03-04 | 国立大学法人金沢大学 | アンドロゲン依存性又は非依存性前立腺癌細胞の抑制用の組成物及びそれを含有する前立腺癌の医薬製剤 |
CN107496414A (zh) * | 2017-09-21 | 2017-12-22 | 上海华堇生物技术有限责任公司 | 柽柳黄素的药物用途 |
CN112645922B (zh) * | 2020-12-24 | 2022-01-07 | 中国人民解放军空军军医大学 | 香豆素类化合物、制备方法及应用 |
CN115894422A (zh) * | 2022-12-26 | 2023-04-04 | 上海中医药大学 | PPARγ激动剂及其组合和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2543550B1 (fr) * | 1983-04-01 | 1985-08-09 | Cortial | Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique |
US4587260A (en) * | 1984-06-21 | 1986-05-06 | Warner-Lambert Company | Dibenzalacetone and benzylcinnamate as non-steroidal anti-inflammatory compounds and compositions thereof |
EP0455448B1 (en) * | 1990-05-01 | 1998-12-09 | R-Tech Ueno Ltd. | Treatment of pancreatic disease with 15-keto-prostaglandin E compounds |
CA2046069C (en) * | 1990-07-10 | 2002-04-09 | Ryuji Ueno | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
AU7718796A (en) * | 1995-11-17 | 1997-06-11 | Pharmacia & Upjohn Company | 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus |
JP2003517288A (ja) * | 1999-05-20 | 2003-05-27 | インサイト・ゲノミックス・インコーポレイテッド | オキシドレダクターゼタンパク質 |
CN1443070A (zh) * | 2000-03-24 | 2003-09-17 | 苏坎波公司 | 包含15-酮基-前列腺素或其衍生物的编程性细胞死亡抑制组合物 |
EP1402026A2 (en) * | 2000-04-18 | 2004-03-31 | Millennium Pharmaceuticals, Inc. | 39228, a human alcohol dehydrogenase and uses therefor |
WO2001080855A1 (en) * | 2000-04-27 | 2001-11-01 | Geron Corporation | Telomerase inhibitors and methods of their use |
US7326734B2 (en) * | 2003-04-01 | 2008-02-05 | The Regents Of The University Of California | Treatment of bladder and urinary tract cancers |
-
2006
- 2006-08-08 EP EP06291283A patent/EP1803809A3/en not_active Withdrawn
- 2006-08-08 US US11/500,579 patent/US20070037193A1/en not_active Abandoned
- 2006-08-09 TW TW095129257A patent/TW200741003A/zh unknown
- 2006-08-10 IL IL177407A patent/IL177407A0/en unknown
- 2006-08-10 JP JP2006218187A patent/JP2007061093A/ja active Pending
- 2006-08-10 SG SG200605449-8A patent/SG130141A1/en unknown
- 2006-08-10 AR ARP060103503A patent/AR054909A1/es not_active Application Discontinuation
- 2006-08-11 ZA ZA200606661A patent/ZA200606661B/xx unknown
- 2006-08-11 AU AU2006203479A patent/AU2006203479A1/en not_active Abandoned
- 2006-08-11 MX MXPA06009161A patent/MXPA06009161A/es not_active Application Discontinuation
- 2006-08-11 CO CO06079383A patent/CO5780135A1/es not_active Application Discontinuation
- 2006-08-11 CA CA002553115A patent/CA2553115A1/en not_active Abandoned
- 2006-08-11 NO NO20063652A patent/NO20063652L/no not_active Application Discontinuation
- 2006-08-12 KR KR1020060076462A patent/KR20080014936A/ko not_active Application Discontinuation
- 2006-08-14 BR BRPI0603206-0A patent/BRPI0603206A/pt not_active Application Discontinuation
- 2006-08-14 CN CNA2006101098017A patent/CN1916167A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
SG130141A1 (en) | 2007-03-20 |
CO5780135A1 (es) | 2007-07-31 |
IL177407A0 (en) | 2006-12-31 |
BRPI0603206A (pt) | 2007-05-15 |
EP1803809A2 (en) | 2007-07-04 |
ZA200606661B (en) | 2008-05-28 |
AU2006203479A1 (en) | 2007-03-01 |
EP1803809A3 (en) | 2007-12-19 |
AR054909A1 (es) | 2007-07-25 |
CA2553115A1 (en) | 2007-02-12 |
MXPA06009161A (es) | 2007-03-21 |
NO20063652L (no) | 2007-02-13 |
CN1916167A (zh) | 2007-02-21 |
US20070037193A1 (en) | 2007-02-15 |
JP2007061093A (ja) | 2007-03-15 |
KR20080014936A (ko) | 2008-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200741003A (en) | Modulation of peroxisome proliferator-activated receptors | |
TW200735862A (en) | Prostaglandin reductase inhibitors | |
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
TW200605868A (en) | Modulation of peroxisome proliferator-activated receptors | |
TW200602048A (en) | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase | |
EA200701229A1 (ru) | Омега-3 жирные кислоты и дислипидемический агент для липидной терапии | |
DE602006010442D1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen | |
MX2009002924A (es) | Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos. | |
EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
MX2010014233A (es) | Compuestos quimicos 251. | |
MX2009002921A (es) | Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico. | |
WO2008022024A3 (en) | Imidazole amines as inhibitors of beta-secretase | |
MX2007004765A (es) | Compuestos y metodos que modulan la actividad de la trombopoyetina. | |
DE602006013883D1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen | |
BR0308813A (pt) | Tratamento de tuberculose usando derivados de pleuromutilina | |
EP1627635A3 (en) | Benzothiazolium compounds for use in methods of inhibiting NO production and TNF alpha and treating coronaviral infection | |
WO2007120485A3 (en) | Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor | |
WO2005082375A3 (en) | Treatment of interstitial cystitis with vitamin d compounds | |
MX366496B (es) | Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso. | |
WO2008048648A3 (en) | Cb1-modulating compounds and their use | |
WO2003105774A3 (en) | COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS THEREOF | |
TW200640467A (en) | Compounds and uses thereof | |
TW200600084A (en) | Anti-coronavirus compounds | |
SE0301885D0 (sv) | New use IV |